Follow
Berbegall AP
Berbegall AP
Pathology department, Medical School of Valencia, INCLIVA, Univesity of Valencia, Valencia, Spain
Verified email at uv.es
Title
Cited by
Cited by
Year
Neuroblastoma patient‐derived orthotopic xenografts retain metastatic patterns and geno‐and phenotypes of patient tumours
N Braekeveldt, C Wigerup, D Gisselsson, S Mohlin, M Merselius, ...
International journal of cancer 136 (5), E252-E261, 2015
1082015
Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort
I Tadeo, AP Berbegall, V Castel, P García-Miguel, R Callaghan, ...
British journal of cancer 115 (4), 480-489, 2016
602016
Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors
S Fransson, M Hansson, K Ruuth, A Djos, A Berbegall, N Javanmardi, ...
Genes, Chromosomes and Cancer 54 (2), 99-109, 2015
592015
Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion
E Villamón, AP Berbegall, M Piqueras, I Tadeo, V Castel, A Djos, ...
PLoS One 8 (1), e53740, 2013
592013
Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy
I Tadeo, AP Berbegall, LM Escudero, T Álvaro, R Noguera
Frontiers in oncology 4, 39, 2014
552014
Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours
N Braekeveldt, C Wigerup, I Tadeo, S Beckman, C Sandén, J Jönsson, ...
Cancer letters 375 (2), 384-389, 2016
522016
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
AP Berbegall, D Bogen, U Pötschger, K Beiske, N Bown, V Combaret, ...
British journal of cancer 118 (11), 1502-1512, 2018
512018
Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma
N Braekeveldt, K Von Stedingk, S Fransson, A Martinez-Monleon, ...
Cancer research 78 (20), 5958-5969, 2018
482018
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN …
R Defferrari, K Mazzocco, IM Ambros, PF Ambros, C Bedwell, K Beiske, ...
British journal of cancer 112 (2), 290-295, 2015
442015
Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration
AP Berbegall, E Villamón, I Tadeo, T Martinsson, A Cañete, V Castel, ...
Neoplasia 16 (6), 471-480, 2014
352014
Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors
AP Berbegall, E Villamon, M Piqueras, I Tadeo, A Djos, PF Ambros, ...
Oncogene 35 (11), 1423-1432, 2016
342016
11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma
JT Siaw, N Javanmardi, J Van den Eynden, DE Lind, S Fransson, ...
Cell reports 32 (12), 2020
332020
Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line
A López-Carrasco, S Martín-Vañó, R Burgos-Panadero, E Monferrer, ...
Journal of Experimental & Clinical Cancer Research 39, 1-13, 2020
322020
A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors
I Tadeo, AP Berbegall, S Navarro, V Castel, R Noguera
Pediatric Blood & Cancer 64 (9), e26449, 2017
312017
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
F Zeka, A Decock, A Van Goethem, K Vanderheyden, F Demuynck, ...
JCI insight 3 (23), 2018
292018
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
A Decock, M Ongenaert, R Cannoodt, K Verniers, B De Wilde, G Laureys, ...
Oncotarget 7 (2), 1960, 2016
282016
Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors
I Tadeo, G Bueno, AP Berbegall, MM Fernández-Carrobles, V Castel, ...
Oncotarget 7 (15), 19935, 2016
272016
9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma
AV Ugolkov, GI Bondarenko, O Dubrovskyi, AP Berbegall, S Navarro, ...
Anti-cancer drugs 29 (8), 717-724, 2018
262018
Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma
I Tadeo, M Piqueras, D Montaner, E Villamón, AP Berbegall, A Cañete, ...
Pediatric research 75 (2), 302-314, 2014
202014
Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors
E Villamón, M Piqueras, AP Berbegall, I Tadeo, V Castel, S Navarro, ...
Histology and histopathology, Vol. 26, nº 3 (2011), 2011
172011
The system can't perform the operation now. Try again later.
Articles 1–20